Titre : Protéines de filaments intermédiaires

Protéines de filaments intermédiaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

RNA, Long Noncoding
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines de filaments intermédiaires : Questions médicales les plus fréquentes", "headline": "Protéines de filaments intermédiaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines de filaments intermédiaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-03", "dateModified": "2025-02-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines de filaments intermédiaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines du cytosquelette", "url": "https://questionsmedicales.fr/mesh/D003598", "about": { "@type": "MedicalCondition", "name": "Protéines du cytosquelette", "code": { "@type": "MedicalCode", "code": "D003598", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Desmine", "alternateName": "Desmin", "url": "https://questionsmedicales.fr/mesh/D003893", "about": { "@type": "MedicalCondition", "name": "Desmine", "code": { "@type": "MedicalCode", "code": "D003893", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220.475.200" } } }, { "@type": "MedicalWebPage", "name": "Protéine gliofibrillaire acide", "alternateName": "Glial Fibrillary Acidic Protein", "url": "https://questionsmedicales.fr/mesh/D005904", "about": { "@type": "MedicalCondition", "name": "Protéine gliofibrillaire acide", "code": { "@type": "MedicalCode", "code": "D005904", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220.475.400" } } }, { "@type": "MedicalWebPage", "name": "Kératine-15", "alternateName": "Keratin-15", "url": "https://questionsmedicales.fr/mesh/D053569", "about": { "@type": "MedicalCondition", "name": "Kératine-15", "code": { "@type": "MedicalCode", "code": "D053569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220.475.450.300.500" } } }, { "@type": "MedicalWebPage", "name": "Vimentine", "alternateName": "Vimentin", "url": "https://questionsmedicales.fr/mesh/D014746", "about": { "@type": "MedicalCondition", "name": "Vimentine", "code": { "@type": "MedicalCode", "code": "D014746", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.220.475.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines de filaments intermédiaires", "alternateName": "Intermediate Filament Proteins", "code": { "@type": "MedicalCode", "code": "D007381", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sarah Köster", "url": "https://questionsmedicales.fr/author/Sarah%20K%C3%B6ster", "affiliation": { "@type": "Organization", "name": "Institute for X-Ray Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany." } }, { "@type": "Person", "name": "Sandrine Etienne-Manneville", "url": "https://questionsmedicales.fr/author/Sandrine%20Etienne-Manneville", "affiliation": { "@type": "Organization", "name": "Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Équipe Labellisée Ligue Contre le Cancer, F-75015 Paris, France. Electronic address: setienne@pasteur.fr." } }, { "@type": "Person", "name": "Charlotta Lorenz", "url": "https://questionsmedicales.fr/author/Charlotta%20Lorenz", "affiliation": { "@type": "Organization", "name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany." } }, { "@type": "Person", "name": "Anna V Schepers", "url": "https://questionsmedicales.fr/author/Anna%20V%20Schepers", "affiliation": { "@type": "Organization", "name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany." } }, { "@type": "Person", "name": "Rudolf E Leube", "url": "https://questionsmedicales.fr/author/Rudolf%20E%20Leube", "affiliation": { "@type": "Organization", "name": "Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "RNA m6A modification facilitates DNA methylation during maize kernel development.", "datePublished": "2023-11-23", "url": "https://questionsmedicales.fr/article/37995374", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/plphys/kiad625" } }, { "@type": "ScholarlyArticle", "name": "RNA G-quadruplex folding is a multi-pathway process driven by conformational entropy.", "datePublished": "2023-11-20", "url": "https://questionsmedicales.fr/article/37986217", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/nar/gkad1065" } }, { "@type": "ScholarlyArticle", "name": "RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.", "datePublished": "2023-11-15", "url": "https://questionsmedicales.fr/article/38035078", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1286700" } }, { "@type": "ScholarlyArticle", "name": "Identification of RBM46 as a novel APOBEC1 cofactor for C-to-U RNA-editing activity.", "datePublished": "2023-10-29", "url": "https://questionsmedicales.fr/article/38708190", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jmb.2023.168333" } }, { "@type": "ScholarlyArticle", "name": "Microarray Expression Profile and Bioinformatic Analysis of Circular RNA in Human Arteriosclerosis Obliterans.", "datePublished": "2023-10-24", "url": "https://questionsmedicales.fr/article/37899885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/PGPM.S424359" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines du cytosquelette", "item": "https://questionsmedicales.fr/mesh/D003598" }, { "@type": "ListItem", "position": 5, "name": "Protéines de filaments intermédiaires", "item": "https://questionsmedicales.fr/mesh/D007381" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines de filaments intermédiaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines de filaments intermédiaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Général", "headline": "Général sur Protéines de filaments intermédiaires", "description": "Erreur lors de la génération.", "url": "https://questionsmedicales.fr/mesh/D007381?mesh_terms=RNA,+Long+Noncoding&page=1000#section-général" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Erreur lors de la génération.", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Veuillez réessayer ultérieurement." } } ] } ] }

Sources (10000 au total)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.

Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies... We first assess feasibility of RNA-sequencing in a multicenter trial (GMMG-MM5, n=604 patients). Next, we use a clinical routine cohort of untreated symptomatic myeloma patients undergoing autologous ... RNA-sequencing is feasible in 90.8% of patients (GMMG-MM5). Actionable immune-oncological targets (n=19) can be divided in those expressed in all normal and >99% of MM-patients (CD38, SLAMF7, BCMA, GP... RNA-sequencing based assessment of risk and targets for first choice treatment is possible in clinical routine....

Microarray Expression Profile and Bioinformatic Analysis of Circular RNA in Human Arteriosclerosis Obliterans.

Arteriosclerosis obliterans (ASO) is the leading cause of nontraumatic lower-extremity amputations. Multiple researches have suggested that circular RNAs (circRNAs) played vital regulatory functions i... This study used microarray analysis to investigate the expression portrait of circRNAs in normal lower extremity arteries and ASO arteries. Bioinformatics analysis was conducted using the KEGG databas... This study described the expression portrait of circRNAs in human ASO arteries, and revealed the molecular background for further investigations of the circRNA regulatory mechanism in the formation an...

Bayesian-frequentist hybrid inference framework for single cell RNA-seq analyses.

Single cell RNA sequencing technology (scRNA-seq) has been proven useful in understanding cell-specific disease mechanisms. However, identifying genes of interest remains a key challenge. Pseudo-bulk ... Motivated by this, we proposed to use the Bayesian-frequentist hybrid (BFH) framework to increase the power.... In our idiopathic pulmonary fibrosis (IPF) case study, we demonstrated that with a proper informative prior, the BFH approach identified more genes of interest. Furthermore, these genes were reasonabl...